The downregulation of IRF4 inhibits NF-κB activity, and conversely, the overexpression of IRF4 enhances NF-κB activity and results in lenalidomide resistance in ABC-DLBCL cells [53]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.